Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan: A real-world administrative database analysis.
Atsunori KashiwagiShingo ShojiYoshinori KosakaiYoko YoshinagaMitsuhiro RokudaPublished in: Journal of diabetes investigation (2023)
SGLT2i were associated with lower HCRU and healthcare costs than DPP4i, suggesting economic benefits with SGLT2i vs DPP4i in type 2 diabetes mellitus management.
Keyphrases